
  
    
      
        Background_NNP
        Endothelial_NNP cell_NN adhesion_NN molecules_NNS (_( '_POS ECAMs_NNP '_POS )_) play_NN
        essential_JJ roles_NNS in_IN the_DT development_NN of_IN chronic_JJ inflammation_NN
        by_IN recruiting_VBG leukocytes_NNS ,_, especially_RB lymphocytes_NNS to_TO
        tissues_NNS ._. ECAMs_NNP support_NN several_JJ forms_NNS of_IN leukocyte_NN adhesion_NN
        including_VBG rolling_VBG ,_, firm_JJ adhesion_NN and_CC extravasation_NN [_NN 1_CD ]_NN ._.
        Infiltration_NNP of_IN tissues_NNS by_IN leukocytes_NNS is_VBZ a_DT common_JJ hallmark_NN
        of_IN many_JJ chronic_JJ inflammatory_JJ states_NNS that_WDT include_VBP the_DT
        inflammatory_JJ bowel_NN diseases_NNS (_( IBD_NNP )_) ,_, ulcerative_JJ colitis_NNS (_( UC_NNP )_) ,_,
        and_CC Crohn_NNP 's_POS disease_NN (_( CD_NNP )_) ._. In_IN the_DT setting_NN of_IN IBD_NNP ,_, the_DT
        expression_NN of_IN ECAMs_NNP like_IN ICAM-_NNP 1_CD ,_, VCAM-_NNP 1_CD ,_, and_CC MAdCAM-_NNP 1_CD
        (_( mucosal_NN addressin_NN cell_NN adhesion_NN molecule-_NN 1_LS )_) is_VBZ observed_VBN in_IN
        experimental_JJ models_NNS of_IN colitis_NNS ,_, [_NN 2_CD 3_CD 4_CD 5_CD ]_NN and_CC also_RB within_IN
        the_DT inflamed_JJ human_JJ colon_NN in_IN Crohn_NNP 's_POS disease_NN and_CC ulcerative_JJ
        colitis_NNS [_NN 6_CD 7_CD ]_NN ._.
        Among_IN the_DT adhesion_NN molecules_NNS up-regulated_JJ in_IN IBD_NNP ,_,
        MAdCAM-_NNP 1_CD ,_, the_DT mucosal_NN cell_NN adhesion_NN molecule_NN ,_, is_VBZ thought_VBN to_TO
        be_VB preeminent_NN in_IN the_DT development_NN of_IN chronic_JJ gut_NN
        inflammation_NN ._. MAdCAM-_NNP 1_CD is_VBZ normally_RB expressed_VBN in_IN the_DT gut_NN ,_,
        and_CC its_PRP$ expression_NN is_VBZ dramatically_RB amplified_VBN during_IN
        inflammation_NN [_NN 2_CD 3_CD ]_NN ._. The_DT functional_JJ significance_NN of_IN
        increased_VBN appearance_NN of_IN MAdCAM-_NNP 1_CD in_IN IBD_NNP is_VBZ supported_VBN by_IN
        several_JJ reports_NNS which_WDT show_VBP that_DT immunoneutralization_NN of_IN
        either_DT MAdCAM-_NNP 1_CD or_CC its_PRP$ ligand_NN ,_, the_DT α_NN 4_CD β_NN 7_CD integrin_NN ,_, attenuate_NN
        inflammation_NN and_CC mucosal_NN damage_NN in_IN animal_NN models_NNS of_IN colitis_NNS
        [_NN 8_CD 9_CD 10_CD ]_NN ._. However_RB ,_, since_IN monoclonal_NN antibodies_NNS directed_VBN
        against_IN other_JJ ECAMs_NNP ,_, particularly_RB VCAM-_NNP 1_CD ,_, can_MD as_RB well_RB
        reduce_VB disease_NN activity_NN in_IN colitis_NNS models_NNS [_NN 11_CD 12_CD 13_CD 14_CD ]_NN ,_,
        the_DT literature_NN suggests_VBZ that_IN MAdCAM-_NNP 1_CD is_VBZ probably_RB
        necessary_JJ ,_, but_CC insufficient_JJ for_IN the_DT maximal_NN penetrance_NN of_IN
        experimental_JJ and_CC probably_RB also_RB clinical_JJ IBD_NNP ._.
        Based_VBN on_IN these_DT findings_NNS ,_, it_PRP is_VBZ apparent_JJ that_IN a_DT better_JJR
        understanding_NN of_IN the_DT mechanisms_NNS regulating_VBG ECAM_NNP expression_NN ,_,
        especially_RB that_IN of_IN MAdCAM-_NNP 1_CD ,_, might_MD help_VB to_TO devise_VB improved_VBN
        therapies_NNS for_IN colitis_NNS ._.
        It_PRP has_VBZ been_VBN suggested_VBN that_IN pathologic_JJ activation_NN of_IN the_DT
        mucosal_NN immune_JJ system_NN in_IN response_NN to_TO antigens_NNS is_VBZ a_DT key_JJ
        factor_NN in_IN the_DT pathogenesis_NNS of_IN IBD_NNP ._. Furthermore_RB ,_, changes_NNS in_IN
        leukocyte_NN migration_NN and_CC cytokine_NN production_NN appear_VBP to_TO
        contribute_VB the_DT perpetuation_NN of_IN IBD_NNP [_NN 15_CD ]_NN ._. Based_VBN on_IN modern_JJ
        advances_NNS ,_, recombinant_JJ anti-inflammatory_JJ cytokines_NNS (_( i_NNP ._. e_SYM ._.
        IL-_NNP 10_CD )_) treatment_NN is_VBZ now_RB being_VBG developed_VBN for_IN experimental_JJ
        colitis_NNS and_CC human_JJ IBD_NNP ._. IL-_NNP 10_CD produced_VBN by_IN macrophages_NNS and_CC
        monocytes_NNS appears_VBZ to_TO limit_VB chronic_JJ inflammation_NN [_NN 16_CD 17_CD 18_CD
        ]_NN ,_, through_IN a_DT decreased_VBN release_NN of_IN inflammatory_JJ factors_NNS
        (_( IL-_NNP 1_CD ,_, IL-_NNP 6_CD ,_, IL-_NNP 12_CD ,_, TNF-α_NNP ,_, GM-CSF_NNP ,_, GCSF_NNP )_) ,_, suppression_NN of_IN
        adhesive_NN determinants_NNS (_( MHC_NNP class_NN II_NNP molecule_NN ,_, β_NN 7_CD )_) ,_, and_CC by_IN
        blocking_VBG ICAM-_NNP 1_CD induction_NN [_NN 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD ]_NN ._.
        Conversely_RB ,_, IL-_NNP 10_CD gene-knockout_JJ mice_NNS develop_VBP a_DT chronic_JJ
        colitis_NNS that_WDT is_VBZ extremely_RB similar_JJ to_TO IBD_NNP [_NN 25_CD ]_NN ._. IL-_NNP 10_CD
        treatment_NN can_MD reduce_VB inflammation_NN in_IN several_JJ models_NNS of_IN
        colitis_NNS [_NN 26_CD 27_CD 28_CD 29_CD 30_CD ]_NN and_CC human_JJ IBD_NNP [_NN 31_CD 32_CD 33_CD 34_CD 35_CD ]_NN
        ._. However_RB ,_, the_DT clinical_JJ efficacy_NN of_IN systemically_RB
        administered_VBN IL-_NNP 10_CD for_IN patients_NNS mild_JJ to_TO moderately_RB active_JJ
        Crohn_NNP 's_POS disease_NN has_VBZ not_RB been_VBN as_RB effective_JJ as_IN hoped_VBN [_NN 33_CD 34_CD
        35_CD ]_NN ._. Furthermore_RB the_DT efficacy_NN of_IN IL-_NNP 10_CD administration_NN in_IN
        mouse_NN colitis_NNS models_NNS is_VBZ contentious_JJ [_NN 36_CD ]_NN ._.
        We_PRP have_VBP described_VBN in_IN vitro_NN that_IN exogenous_JJ IL-_NNP 10_CD can_MD
        block_VB the_DT expression_NN of_IN MAdCAM-_NNP 1_CD in_IN response_NN to_TO TNF-α_NNP ,_, and_CC
        attenuates_NNS lymphocyte_NN adhesion_NN to_TO lymphatic_JJ node_NN derived_VBD
        endothelium_NN under_IN cytokine_NN stimulating_VBG conditions_NNS via_IN NF-kB_NNP
        inhibition_NN [_NN 5_CD ]_NN ._. The_DT purpose_NN of_IN the_DT current_JJ study_NN was_VBD to_TO
        show_VB that_DT induction_NN of_IN endothelial_NN expression_NN of_IN IL-_NNP 10_CD
        through_IN an_DT IL-_NNP 10_CD expression_NN vector_NN attenuates_NNS MAdCAM-_NNP 1_CD
        expression_NN in_IN response_NN to_TO TNF-α_NNP and_CC optimistically_RB suggests_VBZ
        the_DT possibility_NN of_IN targeted_VBN Th_NNP 2_CD -_: cytokine_NN gene_NN therapy_NN in_IN
        IBD_NNP ._.
      
      
        Methods_NNP
        
          Reagents_NNP
          Recombinant_NNP mouse_NN TNF-α_NNP was_VBD purchased_VBN from_IN ENDOGEN_NNP
          (_( Stoughton_NNP ,_, MA_NNP )_) amd_NN plasmid_NN containing_VBG human_JJ IL-_NNP 10_CD
          (_( phIL-_NN 10_CD )_) was_VBD generous_JJ gift_NN from_IN Dr_NNP ._. Meng_NNP X_NNP (_( Thomas_NNP
          Jefferson_NNP University_NNP ,_, PA_NNP )_) ._.
        
        
          Cell_NNP culture_NN
          The_DT SVEC_NNP 4_CD -_: 10_CD line_NN is_VBZ an_DT endothelial_NN cell_NN line_NN derived_VBN
          by_IN SV_NNP 40_CD (_( strain_NN 4_CD A_DT )_) transformation_NN of_IN murine_NN small_JJ vessel_NN
          endothelial_NN cells_NNS ,_, originally_RB isolated_VBN from_IN the_DT axillary_JJ
          lymph_NN node_NN vessels_NNS of_IN an_DT adult_NN male_JJ C_NNP 3_CD H_NNP /_NN Hej_NNP mouse_NN [_NN 37_CD 38_CD
          ]_NN ._. These_DT cell_NN types_NNS were_VBD all_DT maintained_VBN in_IN Dulbecco_NNP 's_POS
          modified_VBN Eagle_NNP 's_POS medium_NN (_( DMEM_NNP )_) with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN
          with_IN 1_CD %_NN antibiotic_JJ /_NN antimycotic_JJ ._. Cells_NNP were_VBD seeded_VBN into_IN
          24_CD -_: well_RB tissue_NN culture_NN plates_NNS at_IN approximately_RB 20_CD ,_, 000_CD
          cells_NNS /_NN cm_NN 2_CD ,_, and_CC cultures_NNS were_VBD used_VBN immediately_RB upon_IN
          reaching_VBG confluence_NN (_( usually_RB 3_CD -_: 4_CD days_NNS after_IN seeding_VBG )_) ._.
        
        
          Lymphocytes_NNP
          The_DT mouse_NN CD_NNP 8_CD +_NN T_NN cell_NN lymphoma_NN TK-_NNP 1_CD cells_NNS (_( that_WDT
          constitutively_RB expresses_VBZ the_DT α_NN 4_CD β_NN 7_CD integrin_NN [_NN 39_CD ]_NN )_) were_VBD
          obtained_VBN as_IN a_DT generous_JJ gift_NN from_IN Dr_NNP ._. Eugene_NNP Butcher_NNP
          (_( Stanford_NNP University_NNP ,_, CA_NNP )_) ._. These_DT cells_NNS were_VBD cultured_JJ in_IN
          RPMI-_NNP 1640_CD medium_NN supplemented_JJ with_IN 10_CD %_NN FCS_NNP and_CC 0_CD ._. 05_CD mM_NN
          2_CD -_: mercaptoethanol_NN (_( minus_CC antibiotic_JJ /_NN antimycotic_JJ )_) ._.
        
        
          IL-_NNP 10_CD gene_NN transfer_NN
          The_DT pCYIL-_NN 10_CD vector_NN is_VBZ an_DT expression_NN vector_NN which_WDT was_VBD
          established_VBN by_IN Dr_NNP ._. Xianmin_NNP Meng_NNP based_VBN on_IN the_DT pCY_NN 4_CD B_NNP vector_NN
          [_NN 40_CD ]_NN ._. Cultured_NNP SVEC_NNP endothelial_NN cells_NNS seeded_VBN in_IN 24_CD
          wells_NNS were_VBD transfected_JJ at_IN 70_CD %_NN confluency_NN with_IN SuperFect_NNP
          (_( Qiagen_NNP )_) ._. Briefly_NNP ,_, 1_CD μg_NN plasmid_NN DNA_NNP was_VBD diluted_VBN with_IN 60_CD
          μl_NN DMEM_NNP and_CC then_RB 5_CD μl_NN Superfect_NNP (_( 3_CD mg_NN /_NN ml_NN )_) was_VBD added_VBN ._.
          After_IN incubation_NN at_IN room_NN temperature_NN for_IN 10_CD min_NN ,_, the_DT
          complex_NN was_VBD mixed_VBN with_IN 350_CD μl_NN medium_NN and_CC added_VBD to_TO the_DT
          each_DT wells_NNS ._. After_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP ,_, 5_CD %_NN CO_NNP 2_CD ,_, the_DT complex_NN was_VBD
          aspirated_JJ and_CC washed_VBN 2_CD times_NNS with_IN medium_NN following_VBG
          replace_VB by_IN 1_CD ml_NN of_IN medium_NN ._. After_IN incubation_NN at_IN 37_CD °_NN C_NNP for_IN
          24_CD h_NN cells_NNS were_VBD stimulated_VBN with_IN TNF-α_NNP ._.
        
        
          Western_JJ analysis_NN of_IN cell_NN lysates_NNS
          24_CD h_NN of_IN IL-_NNP 10_CD gene_NN transfer_NN ,_, monolayers_NNS were_VBD treated_VBN
          with_IN TNF-α_NNP (_( 1_CD ng_NN /_NN ml_NN ,_, 24_CD h_NN )_) ._. All_DT cell_NN samples_NNS were_VBD
          harvested_VBN at_IN 24_CD hours_NNS ._. Equal_NNP quantities_NNS of_IN protein_NN (_( 75_CD
          μg_NN )_) from_IN each_DT sample_NN were_VBD electrophoretically_RB separated_JJ
          on_IN 7_CD ._. 5_CD %_NN SDS-PAGE_NNP gels_NNS ._. Gels_NNP were_VBD transferred_VBN to_TO
          nitrocellulose_NN membranes_NNS (_( Sigma_NNP )_) and_CC blocked_VBN with_IN 5_CD %_NN milk_NN
          powder_NN in_IN PBS_NNP at_IN 4_CD °_NN C_NNP (_( overnight_JJ )_) ._. These_DT membranes_NNS were_VBD
          washed_VBN twice_RB for_IN 10_CD min_NN with_IN wash_NN buffer_NN (_( 0_CD ._. 1_LS %_NN milk_NN
          powder_NN in_IN PBS_NNP )_) ._. Primary_JJ rat_NN anti-mouse_JJ MAdCAM-_NNP 1_CD mAb_NN was_VBD
          added_VBN at_IN a_DT concentration_NN of_IN 10_CD μg_NN /_NN ml_NN and_CC incubated_JJ at_IN
          room_NN temperature_NN for_IN 2_CD h_NN ._. These_DT membranes_NNS were_VBD washed_VBN
          twice_RB with_IN wash_NN buffer_NN ._. Secondary_JJ rabbit_NN anti-rat_JJ
          horseradish_NN peroxidase_NN conjugated_JJ secondary_JJ antibody_NN
          (_( Sigma_NNP )_) was_VBD added_VBN at_IN a_DT 1_CD :_: 2000_CD dilution_NN for_IN 2_CD h_NN ._. Lastly_NNP ,_,
          membranes_NNS were_VBD washed_VBN 3_CD times_NNS and_CC developed_VBN using_VBG the_DT
          enhanced_JJ chemiluminescence_NN (_( ECL_NNP )_) detection_NN system_NN
          (_( Amersham_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP )_) ._. The_DT density_NN of_IN MAdCAM-_NNP 1_CD
          staining_VBG was_VBD measured_VBN by_IN scanning_VBG the_DT 60_CD kD_NN band_NN ,_, using_VBG a_DT
          HP_NNP ScanJet_NNP ™_NN flatbed_JJ scanner_NN ._. Images_NNP were_VBD analyzed_VBN for_IN
          density_NN using_VBG Image_NN Pro_FW Plus_NNP ™_NN image_NN analysis_NN software_NN
          (_( Media_NNP Cybernetics_NNP )_) ._. The_DT data_NNS are_VBP expressed_VBN as_IN a_DT
          percentage_NN of_IN TNF-α-induced_NNP level_NN of_IN density_NN ._. In_IN each_DT
          protocol_NN ,_, treatments_NNS were_VBD performed_VBN at_IN least_JJS in_IN
          triplicate_NN ._.
        
        
          TK-_NNP 1_CD lymphocyte_NN adhesion_NN assay_NN
          Briefly_NNP ,_, TK-_NNP 1_CD cells_NNS were_VBD suspended_VBN in_IN culture_NN medium_NN
          and_CC fluorescence_NN labeled_VBN by_IN incubating_VBG TK-_NNP 1_CD cells_NNS at_IN 2_CD ×_NN
          10_CD 6_CD cells_NNS /_NN ml_NN with_IN 0_CD ._. 02_CD mg_NN fluorescein_NN diacetate_NN (_( FDA_NNP )_)
          (_( Sigma_NNP )_) at_IN 37_CD °_NN C_NNP for_IN 30_CD min_NN ._. The_DT cells_NNS were_VBD then_RB washed_VBN
          twice_RB with_IN ice-cold_JJ HBSS_NNP ,_, spun_VBN at_IN 250_CD g_SYM for_IN 5_CD min_NN to_TO
          remove_VB unincorporated_JJ fluorescence_NN and_CC suspended_VBN in_IN HBSS_NNP ._.
          The_DT TK-_NNP 1_CD lymphocyte_NN cell_NN line_NN used_VBN in_IN this_DT assay_NN
          expresses_VBZ high_JJ levels_NNS of_IN the_DT α_NN 4_CD β_NN 7_CD integrin_NN ,_, [_NN 39_CD 41_CD ]_NN
          which_WDT can_MD interact_NN with_IN multiple_JJ ligands_NNS including_VBG
          mucosal_NN addressin-_NN 1_CD (_( MAdCAM-_NNP 1_LS )_) ,_, as_RB well_RB as_IN VCAM-_NNP 1_CD ,_,
          L-_NNP selectin_NN and_CC fibronectin_NN [_NN 42_CD ]_NN ._. In_IN this_DT system_NN ,_, TNF-α_NNP
          stimulated_VBN TK-_NNP 1_CD adhesion_NN to_TO SVEC_NNP 4_CD -_: 10_CD endothelial_NN cells_NNS is_VBZ
          at_IN least_JJS 50_CD %_NN MAdCAM-_NNP 1_CD dependent_JJ [_NN 41_CD ]_NN ._. SVEC_NNP monolayers_NNS
          were_VBD grown_VBN in_IN 48_CD -_: well_RB plates_NNS as_IN described_VBN ,_, and_CC to_TO
          activate_VBP endothelium_NN ,_, the_DT monolayers_NNS were_VBD incubated_JJ with_IN
          TNF-α_NNP (_( 1_CD ng_NN /_NN ml_NN )_) for_IN 24_CD h_NN ._. Cytokine_NNP treated_VBD endothelial_NN
          cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN media_NNS ._. Labeled_NNP TK-_NNP 1_CD
          cells_NNS were_VBD then_RB added_VBN to_TO the_DT endothelium_NN at_IN a_DT 5_CD :_: 1_CD
          lymphocyte_NN to_TO endothelial_NN cell_NN ratio_NN [_NN 43_CD ]_NN and_CC allowed_VBN
          to_TO bind_NN for_IN 30_CD min_NN under_IN static_JJ conditions_NNS ._. At_IN the_DT end_NN of_IN
          the_DT incubation_NN period_NN ,_, the_DT supernatant_NN was_VBD removed_VBN and_CC
          the_DT monolayers_NNS were_VBD washed_VBN twice_RB with_IN HBSS_NNP ._. Plates_NNP were_VBD
          read_VBN on_IN a_DT Fluoroskan_NNP Ascent_NNP (_( Labsystems_NNP ,_, Helsinki_NNP ,_,
          Finland_NNP )_) set_VBN for_IN excitation_NN at_IN 485_CD nm_NN ,_, and_CC emission_NN at_IN
          515_CD nm_NN ._. Blank_NNP wells_NNS (_( 0_CD %_NN TK-_NNP 1_CD adhesion_NN )_) were_VBD run_VBN as_IN
          controls_NNS that_WDT did_VBD not_RB contain_VB labeled_VBN TK-_NNP 1_CD cells_NNS ._. The_DT
          data_NNS are_VBP expressed_VBN as_IN a_DT percentage_NN of_IN TNF-α-induced_NNP level_NN
          of_IN fluorescence_NN ._. In_IN each_DT protocol_NN ,_, treatments_NNS were_VBD
          performed_VBN at_IN least_JJS in_IN triplicate_NN ._.
        
        
          Statistical_NNP analysis_NN
          All_DT values_NNS are_VBP expressed_VBN as_IN mean_NN ±_NN SD_NNP ._. Data_NNP were_VBD
          analyzed_VBN using_VBG multiple_JJ comparisons_NNS ._. Probability_NNP (_( 
          P_NN )_) values_NNS of_IN <_NN 0_CD ._. 05_CD were_VBD
          considered_VBN significant_JJ ._.
        
      
      
        Results_NNS
        
          Secretion_NNP of_IN human_JJ IL-_NNP 10_CD concentration_NN by_IN
          transfected_JJ endothelial_NN cells_NNS
          To_TO screen_VB for_IN the_DT efficacy_NN of_IN IL-_NNP 10_CD transfected_JJ SVEC_NNP ,_,
          we_PRP initially_RB measured_VBD the_DT IL-_NNP 10_CD concentration_NN in_IN the_DT
          medium_NN prior_RB to_TO gene_NN transfection_NN ._. There_EX was_VBD no_DT
          detectable_JJ human_JJ IL-_NNP 10_CD signal_NN in_IN the_DT non-transfected_JJ cell_NN
          medium_NN (_( control_NN )_) ,_, nor_CC any_DT mouse_NN IL-_NNP 10_CD (_( 
          data_NNS not_RB shown_VBN )_) ._. However_RB ,_, the_DT
          medium_NN from_IN the_DT IL-_NNP 10_CD transfected_JJ SVEC_NNP medium_NN showed_VBD a_DT
          large_JJ and_CC significant_JJ increase_NN in_IN the_DT IL-_NNP 10_CD concentration_NN
          (_( 1209_CD ±_NN 2_CD pg_NN /_NN ml_NN )_) at_IN 48_CD h_NN after_IN IL-_NNP 10_CD gene_NN transfection_NN
          (_( Figure_NN 1_LS )_) ._. Importantly_NNP ,_, SVEC_NNP cells_NNS transfected_JJ with_IN this_DT
          vector_NN showed_VBD no_DT evidence_NN of_IN toxicity_NN ,_, altered_VBN
          proliferation_NN and_CC morphologically_RB were_VBD indistinguishable_JJ
          from_IN mock-transfected_JJ and_CC untreated_JJ controls_NNS ._.
        
        
          MAdCAM-_NNP 1_CD expression_NN in_IN IL-_NNP 10_CD gene_NN transfected_JJ
          endothelial_NN cells_NNS
          The_DT anti-inflammatory_JJ effect_NN of_IN IL-_NNP 10_CD gene_NN
          transfection_NN in_IN endothelial_NN cells_NNS was_VBD measured_VBN by_IN the_DT
          reduction_NN in_IN the_DT expression_NN of_IN the_DT endothelial_NN cell_NN
          adhesion_NN molecule_NN MAdCAM-_NNP 1_CD induced_VBN by_IN TNF-α_NNP (_( 1_CD ng_NN /_NN ml_NN ,_, 24_CD
          h_NN )_) ._. TNF-α_NNP strongly_RB induced_VBD expression_NN of_IN MAdCAM-_NNP 1_CD ._. This_DT
          effect_NN was_VBD significantly_RB reduced_VBN by_IN IL-_NNP 10_CD gene_NN
          transfection_NN (_( Fig_NNP ._. 2_LS )_) ._. Alone_NNP ,_, the_DT IL-_NNP 10_CD gene_NN transfection_NN
          had_VBD no_DT effect_NN on_IN MAdCAM-_NNP 1_CD expression_NN ._.
        
        
          α_NN 4_CD β_NN 7_CD integrin_NN lymphocyte_NN adhesion_NN to_TO IL-_NNP 10_CD gene_NN
          transfected_JJ endothelial_NN cells_NNS
          Having_VBG established_VBN that_IN IL-_NNP 10_CD gene_NN transfection_NN exerts_NNS
          a_DT significant_JJ protective_JJ effect_NN against_IN TNF-α_NNP stimulated_VBN
          endothelial_NN MAdCAM-_NNP 1_CD induction_NN ,_, we_PRP next_RB examined_VBD the_DT
          effects_NNS of_IN IL-_NNP 10_CD gene_NN transfection_NN on_IN the_DT adhesion_NN of_IN
          α_NN 4_CD β_NN 7_CD expressing_VBG lymphocytes_NNS (_( using_VBG the_DT mouse_NN cell_NN line_NN
          TK-_NNP 1_LS )_) to_TO endothelial_NN monolayers_NNS ._. TNF-α_NNP stimulation_NN (_( 1_CD
          ng_NN /_NN ml_NN ,_, 24_CD h_NN )_) significantly_RB increased_VBD the_DT adhesion_NN of_IN TK-_NNP 1_CD
          lymphocytes_NNS to_TO SVEC_NNP monolayers_NNS ._. IL-_NNP 10_CD gene_NN transfection_NN
          significantly_RB reduced_VBD TK-_NNP 1_CD adhesion_NN in_IN response_NN to_TO TNF-α_NNP
          stimulation_NN at_IN 24_CD h_NN (_( Fig_NNP ._. 3_LS )_) ._. Alone_NNP ,_, IL-_NNP 10_CD gene_NN
          transfection_NN did_VBD not_RB modify_VB the_DT basal_NN level_NN of_IN lymphocyte_NN
          adhesion_NN to_TO the_DT endothelium_NN without_IN TNF-α_NNP treatment_NN ._.
        
      
      
        Discussion_NNP
        MAdCAM-_NNP 1_CD is_VBZ a_DT 60_CD kDa_NN endothelial_NN cell_NN surface_NN molecule_NN
        that_WDT is_VBZ strongly_RB expressed_VBN by_IN mucosal_NN endothelial_NN cells_NNS ,_,
        particularly_RB following_VBG exposure_NN of_IN these_DT cells_NNS to_TO
        pro-inflammatory_JJ cytokines_NNS such_JJ as_IN TNF-α_NNP ._. Expression_NNP of_IN
        MAdCAM-_NNP 1_CD has_VBZ also_RB been_VBN reported_VBN in_IN the_DT brain_NN ,_, and_CC in_IN the_DT
        heart_NN [_NN 44_CD 45_CD ]_NN ;_: based_VBN on_IN these_DT findings_NNS ,_, it_PRP is_VBZ now_RB been_VBN
        suggested_VBN that_IN MAdCAM-_NNP 1_CD might_MD play_VB roles_NNS in_IN chronic_JJ
        inflammation_NN of_IN these_DT organs_NNS as_RB well_RB ._.
        With_IN respect_NN to_TO inflammatory_JJ bowel_NN disease_NN ,_, MAdCAM-_NNP 1_CD
        appears_VBZ to_TO be_VB essential_JJ to_TO the_DT lymphocyte_NN homing_VBG to_TO the_DT
        mucosa_NN associated_VBN lymphoid_NN tissue_NN (_( MALT_NNP )_) [_NN 6_CD 37_CD 38_CD 46_CD ]_NN ._.
        Since_IN MAdCAM-_NNP 1_CD is_VBZ normally_RB expressed_VBN mainly_RB within_IN the_DT gut_NN
        microvasculature_NN ,_, and_CC is_VBZ dramatically_RB amplified_VBN during_IN IBD_NNP ,_,
        it_PRP has_VBZ been_VBN suggested_VBN that_WDT increased_VBD MAdCAM-_NNP 1_CD expression_NN
        contributes_VBZ to_TO the_DT etiology_NN of_IN IBD_NNP through_IN its_PRP$ ability_NN to_TO
        direct_VB homing_VBG of_IN lymphocytes_NNS to_TO the_DT gut_NN ._. This_DT notion_NN is_VBZ
        well_RB supported_VBN by_IN several_JJ reports_NNS that_WDT show_NN that_IN antibodies_NNS
        directed_VBN against_IN either_DT MAdCAM-_NNP 1_CD ,_, or_CC its_PRP$ lymphocyte_NN ligand_NN ,_,
        the_DT α_NN 4_CD β_NN 7_CD integrin_NN will_MD significantly_RB attenuate_NN several_JJ
        indices_NNS of_IN gut_NN damage_NN in_IN experimental_JJ models_NNS of_IN colitis_NNS [_NN 9_CD
        47_CD ]_NN ._.
        Several_JJ studies_NNS have_VBP indicated_VBN that_DT T_NN helper_NN (_( Th_NNP 1_LS )_)
        immune_JJ response_NN has_VBZ important_JJ roles_NNS in_IN the_DT development_NN of_IN
        IBD_NNP [_NN 48_CD 49_CD 50_CD ]_NN ._. Moreover_RB ,_, dysregulation_NN of_IN cytokine_NN
        networks_NNS is_VBZ involved_VBN in_IN Th_NNP 1_CD -_: dominant_JJ immune_JJ responses_NNS in_IN
        IBD_NNP [_NN 48_CD 49_CD 50_CD ]_NN ._. Among_IN the_DT Th_NNP 1_CD cytokines_NNS ,_, TNF-α_NNP is_VBZ
        thought_VBN to_TO be_VB perhaps_RB the_DT most_RBS important_JJ cytokine_NN
        responsible_JJ for_IN driving_VBG the_DT onset_NN and_CC evolution_NN of_IN IBD_NNP ._.
        Because_IN of_IN this_DT prime_JJ role_NN of_IN TNF-α_NNP in_IN IBD_NNP ,_, anti-_NN TNF-α_NNP
        antibody_NN therapy_NN has_VBZ been_VBN very_RB successfully_RB used_VBN in_IN IBD_NNP to_TO
        reduce_VB both_DT colonic_JJ injury_NN and_CC expression_NN of_IN ECAMs_NNP in_IN IBD_NNP [_NN
        51_CD ]_NN ._.
        IL-_NNP 10_CD ,_, a_DT cytokine_NN produced_VBN by_IN activated_VBN macrophages_NNS and_CC
        Th_NNP 2_CD -_: type_NN T_NN cells_NNS ,_, has_VBZ crucial_JJ inhibitory_NN effect_NN against_IN
        several_JJ Th-_NNP 1_CD type_NN immune_JJ responses_NNS ,_, such_JJ as_IN the_DT
        antigen-presenting_JJ functions_NNS of_IN monocytes_NNS and_CC macrophages_NNS [_NN
        52_CD 53_CD ]_NN ._. IL-_NNP 10_CD may_MD play_VB an_DT important_JJ role_NN in_IN preventing_VBG
        the_DT induction_NN of_IN IBD_NNP ,_, since_IN animals_NNS deficient_NN in_IN IL-_NNP 10_CD will_MD
        develop_VB colitis_NNS spontaneously_RB ,_, and_CC low_JJ levels_NNS of_IN IL-_NNP 10_CD are_VBP
        positively_RB correlated_JJ with_IN recurrences_NNS of_IN Crohn_NNP 's_POS disease_NN [_NN
        25_CD 54_CD ]_NN ._. However_RB ,_, unlike_IN TNF-α_NNP based_VBD therapies_NNS ,_, the_DT
        administration_NN of_IN recombinant_JJ IL-_NNP 10_CD (_( rIL-_NN 10_CD )_) shows_VBZ poor_JJ
        clinical_JJ efficacy_NN ._. This_DT may_MD reflect_VB the_DT fact_NN that_IN TNF-α_NNP
        therapies_NNS for_IN IBD_NNP are_VBP aimed_VBN at_IN efficiently_RB clearing_VBG TNF-α_NNP ,_,
        while_IN IL-_NNP 10_CD therapies_NNS must_MD 
        increase_VB IL-_NNP 10_CD and_CC recombinant_JJ IL-_NNP 10_CD
        is_VBZ likely_JJ too_RB rapidly_RB cleared_VBD from_IN the_DT circulation_NN after_IN 
        in_IN vivo_NN administration_NN to_TO provide_VB a_DT
        uniform_NN protection_NN [_NN 55_CD ]_NN ._. On_IN the_DT other_JJ hand_NN ,_, IL-_NNP 10_CD 
        gene_NN transfer_NN technology_NN has_VBZ been_VBN
        used_VBN with_IN some_DT success_NN in_IN models_NNS of_IN colitis_NNS ,_, however_RB its_PRP$
        effectiveness_NN is_VBZ also_RB variable_JJ ._. One_CD reason_NN for_IN this_DT
        variability_NN may_MD be_VB that_IN the_DT final_JJ serum_NN IL-_NNP 10_CD concentration_NN
        of_IN gene-transfected_JJ mice_NNS might_MD be_VB below_IN the_DT critical_JJ
        threshold_NN needed_VBN for_IN gut_NN protection_NN [_NN 55_CD 56_CD ]_NN ._. Therefore_RB
        targeting_VBG of_IN the_DT IL-_NNP 10_CD gene_NN to_TO the_DT inflamed_JJ colon_NN should_MD
        ideally_RB exploit_VB tissue_NN (_( i_NNP ._. e_SYM ._. gut_NN )_) specific_JJ promoters_NNS to_TO
        control_VB selective_JJ organ_NN gene_NN transfer_NN technology_NN ,_,
        endothelial_NN specific_JJ promoters_NNS and_CC also_RB organ_NN specific_JJ
        intra-arterial_JJ injection_NN of_IN vector_NN to_TO activate_VBP some_DT genes_NNS
        in_IN specific_JJ locations_NNS [_NN 57_CD ]_NN ._.
        Administration_NNP of_IN IL-_NNP 10_CD 
        in_IN vitro_NN prevents_VBZ TNF-α_NNP stimulated_VBN
        expression_NN of_IN MAdCAM-_NNP 1_CD ,_, and_CC also_RB blocks_VBZ lymphocyte_NN adhesion_NN
        to_TO endothelial_NN cells_NNS to_TO the_DT same_JJ extent_NN as_IN dexamethasone_NN
        treatment_NN ,_, currently_RB a_DT key_JJ therapy_NN in_IN IBD_NNP [_NN 5_CD ]_NN ._.
        Interestingly_RB ,_, the_DT low_JJ basal_NN levels_NNS of_IN MAdCAM-_NNP 1_CD expressed_VBN
        by_IN control_NN (_( cytokine_NN unstimulated_JJ )_) cells_NNS were_VBD not_RB affected_VBN
        by_IN IL-_NNP 10_CD transfection_NN ._. This_DT suggests_VBZ that_DT basal_NN expression_NN
        of_IN MAdCAM-_NNP 1_CD ,_, is_VBZ IL-_NNP 10_CD independent_JJ ,_, while_IN cytokine_NN
        stimulated_VBN MAdCAM-_NNP 1_CD 
        is_VBZ modulated_JJ by_IN IL-_NNP 10_CD ._. While_IN we_PRP
        previously_RB showed_VBD that_DT delivery_NN of_IN IL-_NNP 10_CD to_TO the_DT endothelium_NN
        
        in_IN vitro_NN is_VBZ protective_JJ against_IN TNF-α_NNP
        [_NN 5_CD ]_NN ,_, 
        in_IN vivo_NN IL-_NNP 10_CD has_VBZ not_RB been_VBN as_IN
        effective_NN ._. There_RB are_VBP at_IN least_JJS two_CD regulating_VBG pathways_NNS in_IN
        ECAM_NNP expression_NN ,_, one_CD is_VBZ a_DT cytokine-dependent_JJ pathway_NN which_WDT
        is_VBZ widely_RB studied_VBN and_CC the_DT other_JJ is_VBZ cytokine-independent_JJ [_NN
        58_CD ]_NN ._. IL-_NNP 10_CD apparently_RB prevents_VBZ cytokine-induced_JJ NF-kB_NNP
        binding_JJ activity_NN to_TO the_DT ECAM_NNP promoter_NN [_NN 59_CD ]_NN and_CC blocks_VBZ the_DT
        excessive_JJ expression_NN of_IN ECAMs_NNP in_IN cytokine-mediated_JJ
        inflammatory_JJ conditions_NNS ._. In_IN this_DT regard_NN ,_, IL-_NNP 10_CD has_VBZ been_VBN
        used_VBN as_IN a_DT treatment_NN in_IN inflammatory_JJ diseases_NNS ,_, like_IN IBD_NNP for_IN
        precisely_RB this_DT reason_NN :_: because_IN it_PRP has_VBZ few_JJ effects_NNS at_IN sites_NNS
        remote_JJ from_IN inflammation_NN ._. Similarly_RB ,_, we_PRP found_VBD that_IN IL-_NNP 10_CD
        transfection_NN did_VBD not_RB affect_VB cell_NN morphology_NN ,_, total_JJ protein_NN
        level_NN ,_, or_CC the_DT expression_NN of_IN actin_NN and_CC vimentin_NN in_IN these_DT
        cells_NNS (_( measured_VBN by_IN Ponceau_NNP red_JJ S_NNP staining_VBG density_NN on_IN
        immunoblots_NNS )_) ._. Therefore_RB methods_NNS like_IN endothelial_NN gene_NN
        transfection_NN /_NN transfer_NN 
        in_IN vivo_NN may_MD effectively_RB maintain_VB
        adequate_JJ IL-_NNP 10_CD concentrations_NNS near_IN the_DT endothelial_NN cells_NNS
        that_WDT finally_RB achieve_VB the_DT protection_NN against_IN cytokines_NNS that_WDT
        is_VBZ not_RB uniformly_RB produced_VBN by_IN systemic_JJ IL-_NNP 10_CD
        administration_NN ._.
        The_DT most_RBS important_JJ index_NN for_IN how_WRB well_RB gene_NN mediated_JJ
        recombinant_JJ IL-_NNP 10_CD delivery_NN might_MD work_VB in_IN IBD_NNP appears_VBZ to_TO be_VB
        measurement_NN of_IN the_DT inhibition_NN of_IN lymphocyte-endothelium_JJ
        binding_JJ mediated_JJ by_IN TNF-α_NNP induced_VBD MAdCAM-_NNP 1_CD expression_NN ._. In_IN
        this_DT experiment_NN ,_, IL-_NNP 10_CD induction_NN in_IN the_DT endothelium_NN
        efficiently_RB blocked_VBD TNF-α_NNP induced_VBD MAdCAM-_NNP 1_CD expression_NN and_CC
        α_NN 4_CD β_NN 7_CD -_: dependent_JJ lymphocyte_NN adhesion_NN on_IN SVEC_NNP endothelial_NN
        cells_NNS ._. IL-_NNP 10_CD deficiency_NN in_IN colitis_NNS increases_NNS expression_NN of_IN
        several_JJ ECAMs_NNP including_VBG ICAM-_NNP 1_CD ,_, VCAM-_NNP 1_CD and_CC MAdCAM-_NNP 1_CD [_NN 60_CD ]_NN
        ._. We_PRP performed_VBD an_DT experiment_NN ,_, where_WRB under_IN non-stimulated_JJ
        conditions_NNS only_RB 55_CD ._. 7_CD ±_NN 5_CD ._. 4_CD %_NN as_IN many_JJ of_IN the_DT TK-_NNP 1_CD lymphocytes_NNS
        bound_VBN to_TO SVEC_NNP compared_VBD to_TO TNF-α_NNP stimulation_NN (_( 100_CD %_NN ,_, or_CC
        '_POS maximal_NN '_'' binding_JJ )_) ._. TK-_NNP 1_CD were_VBD seen_VBN to_TO interact_NN with_IN SVEC_NNP
        through_IN ICAM-_NNP 1_CD as_RB well_RB MAdCAM-_NNP 1_CD ,_, but_CC not_RB VCAM-_NNP 1_CD ,_, since_IN an_DT
        antibody_NN against_IN MAdCAM-_NNP 1_CD reduced_VBN adhesion_NN to_TO 27_CD ±_NN 4_CD ._. 6_CD %_NN of_IN
        maximum_NN and_CC an_DT anti-_NN ICAM-_NNP 1_CD reduced_VBN adhesion_NN to_TO 54_CD ._. 6_CD ±_NN 8_CD ._. 3_CD %_NN
        of_IN maximum_NN ;_: anti-_NN VCAM-_NNP 1_CD reduced_VBN adhesion_NN to_TO 91_CD %_NN of_IN maximum_NN
        (_( blocks_NNS lymphocyte_NN adhesion_NN to_TO endothelial_NN cells_NNS (_( 
        data_NNS not_RB shown_VBN )_) ._. Therefore_RB we_PRP feel_VBP
        that_DT adhesion_NN in_IN this_DT system_NN is_VBZ mostly_RB MAdCAM-_NNP 1_CD
        dependent_JJ ._.
        IL-_NNP 10_CD transfection_NN of_IN endothelial_NN cells_NNS reduced_VBD MAdCAM-_NNP 1_CD
        expression_NN by_IN 42_CD %_NN (_( following_VBG TNF-α_NNP stimulation_NN )_) and_CC reduced_VBN
        TK-_NNP 1_CD adhesion_NN by_IN 50_CD %_NN ._. Therefore_RB ,_, these_DT data_NNS suggest_VBP that_IN
        the_DT reduction_NN of_IN TK-_NNP 1_CD adhesion_NN is_VBZ approximately_RB 84_CD %_NN
        (_( 42_CD %_NN /_NN 50_CD %_NN )_) MAdCAM-_NNP 1_CD dependent_JJ ,_, and_CC that_IN the_DT remaining_VBG 16_CD %_NN of_IN
        adhesion_NN depends_VBZ on_IN other_JJ ECAMs_NNP ,_, (_( such_JJ as_IN ICAM-_NNP 1_LS )_) ._.
        Although_IN tissue_NN specific_JJ promoters_NNS might_MD further_VB
        increase_VB the_DT organ_NN specificity_NN and_CC transgene_NN delivery_NN of_IN
        this_DT approach_NN ,_, they_PRP have_VBP not_RB been_VBN evaluated_VBN in_IN this_DT report_NN ._.
        Our_PRP$ findings_NNS suggest_VBP that_IN lymphatic_JJ or_CC gut_NN endothelial_NN
        transfection_NN with_IN Th_NNP 2_CD cytokines_NNS like_IN IL-_NNP 10_CD may_MD be_VB an_DT
        effective_JJ method_NN to_TO reduce_VB important_JJ clinical_JJ symptoms_NNS
        associated_VBN with_IN IBD_NNP which_WDT are_VBP mediated_JJ by_IN MAdCAM-_NNP 1_CD
        dependent_JJ lymphocyte_NN adhesion_NN ._.
      
      
        Abbreviations_NNP
        MAdCAM-_NNP 1_CD (_( mucosal_NN addressin_NN cell_NN adhesion_NN molecule-_NN 1_LS )_) ,_,
        IL-_NNP 10_CD (_( Interleukin-_NNP 10_CD )_) ,_, HEV_NNP (_( high_JJ endothelial_NN venular_NN )_) ,_,
        ECAMs_NNP (_( endothelial_NN cell_NN adhesion_NN molecules_NNS )_) ,_, IBD_NNP
        (_( inflammatory_JJ bowel_NN diseases_NNS )_) ,_, UC_NNP (_( ulcerative_JJ colitis_NNS )_) ,_, CD_NNP
        (_( Crohn_NNP 's_POS disease_NN )_) ,_, ICAM-_NNP 1_CD (_( intracellular_NN adhesion_NN molecule_NN
        1_LS )_) ,_, VCAM-_NNP 1_CD (_( vascular_NN adhesion_NN molecule_NN 1_LS )_) ,_, NF-kB_NNP (_( nuclear_JJ
        transfection_NN factor_NN kB_NN )_) ,_, TNF-α_NNP (_( tumor_NN necrosis_NNS factor_NN
        alpha_NN )_) ,_, GM-CSF_NNP (_( granulocyte-macrophage_JJ colony-stimulating_JJ
        factor_NN )_) ,_, GCSF_NNP (_( granulocute_NN colony_NN stimulating_VBG factor_NN )_) ,_, ECL_NNP
        (_( enhanced_JJ chemiluminescence_NN )_)
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
